The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology - 13/01/15
, Amit Garg, MD h, Joseph F. Merola, MD, MMSc i, Mara Maccarone j, Robin Christensen, MSc, PhD kAbstract |
As quality standards are increasingly in demand throughout medicine, dermatology needs to establish outcome measures to quantify the effectiveness of treatments and providers. The International Dermatology Outcome Measures Group was established to address this need. Beginning with psoriasis, the group aims to create a tool considerate of patients and providers using the input of all relevant stakeholders in assessment of disease severity and response to treatment. Herein, we delineate the procedures through which consensus is being reached and the future directions of the project.
Le texte complet de cet article est disponible en PDF.Key words : body surface area, Delphi exercises, Dermatology Life Quality Index, disease severity, International Dermatology Outcome Measures, National Psoriasis Foundation, Outcome Measures in Rheumatology, patient-centered outcome measures, Physician Global Assessment, psoriasis, Psoriasis Area and Severity Index, psoriatic arthritis, quality of life
Abbreviations used : IDEOM, OMERACT, PASI
Plan
| Funding sources: None. |
|
| Disclosure: Dr Gottlieb maintains current consulting/advisory board agreements with Amgen Inc, Astellas, Centocor (Janssen), Celgene Corp, Bristol Meyers Squibb Co, Beiersdorf Inc, Abbott Labs (Abbvie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Eli Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, and Sanofi Aventis. Dr Armstrong served as a consultant and was investigator for Abbvie, Amgen Inc, Janssen, Eli Lilly, Pfizer, and Merck. Dr Abernethy served on the advisory board of Abbvie and as speaker for Pfizer receiving honoraria and is an employee for National Psoriasis Foundation receiving salary. Dr Duffin served on the advisory board and was consultant and investigator for Amgen Inc, Janssen, Eli Lilly, and Pfizer; served as consultant and investigator for VBL Therapeutics receiving honoraria and salary; was investigator for Abbvie receiving salary; and served as consultant for Bristol Myers Squibb Co receiving honoraria. Dr Garg served on the advisory board of Eli Lilly, Amgen Inc, Abbvie, Genentech, and Pfizer receiving honoraria. Dr Merola served on the advisory board and was investigator for Amgen Inc; was on the advisory board on Eli Lilly and Novartis; was an investigator for Pfizer and Biogen; was speaker for Abbvie; and had an “other” relationship with Abbvie and Biogen receiving honoraria. Ms Maccarone is the founder of Associazione per la Difesa degli Psoriasici–Italian Association for Psoriasis receiving no compensation. Dr Christensen receives no compensation from industry. Tufts Medical Center received research/educational grants from Centocor (Janssen), Amgen Inc. Abbott Labs (Abbvie), Novartis, Celgene, Pfizer, Eli Lilly, Coronado, Levia, and Merck. Ms Levin and Dr Bhushan have no conflicts of interest to declare. |
Vol 72 - N° 2
P. 345-348 - février 2015 Retour au numéro
Article précédent
- Shared medical appointments for the preoperative consultation visit of Mohs micrographic surgery
- Thomas J. Knackstedt, Faramarz H. Samie
- A high-tech ethical twist on the curbside consult
- Andrew Kelsey, Jane M. Grant-Kels, Michael Payette
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?